轉(zhuǎn)化性肺癌研究(TLCR, Transl肺癌研究，ISSN 2218-6751;isn 2226-4477)是一份國(guó)際、同行評(píng)議、開放獲取的期刊，成立于2012年3月。TLCR由科學(xué)引文索引擴(kuò)展(SCIE)、PubMed/PubMed中心、Scopus和化學(xué)文摘服務(wù)(CAS)數(shù)據(jù)庫(kù)索引。自2013年2月起，每季度出版一期，每月出版一期。它提供實(shí)用的最新信息，預(yù)防，早期發(fā)現(xiàn)，診斷和治療肺癌和相關(guān)的胸部疾病。其感興趣的具體領(lǐng)域包括但不限于，多模式治療，標(biāo)記物，成像，腫瘤生物學(xué)，病理學(xué)，化學(xué)預(yù)防，以及與肺癌和相關(guān)胸部疾病相關(guān)的技術(shù)進(jìn)步。

Translational Lung Cancer Research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by Science Citation Index Expanded (SCIE), PubMed/PubMed Central, Scopus and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer and related thoracic diseases. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.